◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › GUTS

Fractyl Health, Inc. (GUTS) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-09

Fractyl Health, Inc. (GUTS) operates in the Biotechnology industry and is headquartered in Burlington, United States with about 100 employees. Its market capitalization is roughly $126 million. In the fiscal year ended 2025-12-31, GUTS reported $0M in revenue and ($141M) in net income.

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.

Interactive charts & full statements →

GUTS Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$0M$0M$0M$0M
Gross Profit$0M$0M$0M$0M
Operating Income (EBIT)($97M)($94M)($51M)($49M)
Net Income($141M)($69M)($77M)($46M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GUTS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$0M$0M$0M$0M$0M
Gross Profit$0M$0M$0M$0M$0M
Operating Income (EBIT)($21M)($23M)($23M)($26M)($25M)
Net Income$9M($44M)($46M)($28M)($24M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GUTS Free Cash Flow History

GUTS Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$121M$108M$76M$61M
Total Liabilities$112M$80M$401M$313M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GUTS viewer.

Other Companies in Biotechnology

← GUTAll stocksGV →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.